Skip to main content

Table 1 Differences in baseline characteristics between psoriasis with and without psoriatic arthritis a

From: The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio

Characteristic

PsA (n=136)

PsO (n=152)

p-valueb

Male (n=189)

Female (n=99)

p-valueb

Age, mean (SD), y

50.45 (13.12)

42.87 (15.63)

<.0001

46.79 (14.72)

45.79 (15.46)

.5627

Age at disease onset, mean (SD), y

36.00 (16.07)

31.35 (15.83)

.0052

35.15 (14.98)

30.50 (17.68)

.0021

Disease duration, mean (SD), y

14.51 (10.22)

11.52 (9.89)

.0061

11.65 (9.27)

15.39 (11.26)

.0089

Height, mean (SD), m

1.67 (0.08)

1.68 (0.08)

.8273

1.71 (0.06)

1.60 (0.06)

<.0001

Weight, mean (SD), kg

70.21 (12.28)

69.04 (13.28)

.4500

73.20 (11.43)

62.81 (12.56)

<.0001

BMI

25.01 (3.44)

24.48 (3.62)

.2158

24.85 (3.22)

24.49 (4.09)

.0865

PASI at baseline

14.04 (8.37)

13.78 (5.47)

.7491

14.74 (7.25)

12.29 (6.16)

.0045

PASI at 12W

4.58 (4.69)

3.55 (3.52)

.0354

4.41 (4.48)

3.31 (3.29)

.0288

Mean PASI change from baseline, mean (SD)

63.33 (31.50)

70.82 (28.28)

.0236

66.12 (30.27)

69.51 (29.57)

.2990

BSA at baseline

26.91 (22.64)

26.22 (17.42)

.7713

27.83 (20.08)

24.08 (19.77)

.0676

BSA at 12W

9.55 (16.80)

6.75 (12.20)

.0518

9.11 (16.28)

6.07 (10.45)

.0125

Mean BSA change from baseline, mean (SD)

60.75 (42.16)

71.38 (38.12)

.0105

65.11 (37.95)

68.74 (44.72)

.0813

Cumulative dose of MTX, mean (SD), mg

138.1 (19.85)

138.4 (20.00)

.8869

139.8 (19.36)

135.3 (20.66)

.0314

Hypertension

60 (44.1)

41 (27.0)

.0029

71 (37.6)

30 (30.3)

.2434

Diabetes

28 (20.6)

25 (16.4)

.4466

32 (16.9)

21 (21.2)

.4240

Smoking

36 (26.5)

52 (34.2)

.1613

86 (45.5)

2 (2.0)

<.0001

Alcohol consumption

36 (26.5)

44 (28.9)

.6933

74 (39.2)

6 (6.1)

<.0001

Hypercholesterolemia (>5.9 mmol/L)

23 (16.9)

10 (6.6)

.0087

14 (7.4)

19 (19.2)

.0056

Hypertriglyceridemia (>1.8 mmol/L)

51 (37.5)

42 (27.6)

.0786

61 (32.3)

32 (32.3)

1.000

Increased LDL (>3.7mmol/L)

28 (20.6)

21 (13.8)

.1574

35 (18.5)

14 (14.1)

.4106

Hyperlipoproteinemia (a) (>300mg/L)

18 (13.2)

19 (12.5)

.8620

21 (11.1)

16 (16.2)

.2662

Arthritis

   

86 (45.5)

50 (50.5)

0.4569

Male

86 (63.2)

103 (67.8)

.4569

   
  1. Abbreviation: BMI body mass index (calculated as weight in kilograms divided by height in meters squared), BSA body surface area, PASI Psoriasis Area Severity Index
  2. aData are presented as number (percentage) of patients unless otherwise indicated
  3. bMann-Whitney test, unpaired t test, or Fisher exact test was used when appropriate. p < .05 is considered to be statistically significant
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us